Funding for this research was provided by:
F. Hoffmann-La Roche
Received: 19 June 2018
Accepted: 29 August 2018
First Online: 19 September 2018
: MW, CH, SSu, and RP were employees of Genentech Inc., South San Francisco, CA, USA at the time of the study.
: This study was conducted at 21 sites in the US, one site in Spain, and one site in France. The study protocol was approved by the respective institutional review boards prior to participant recruitment and was conducted in accordance with US Food and Drug Administration regulations, International Council on Harmonization E6 Guideline for Good Clinical Practice, and applicable local, state, federal, and country laws. Written informed consent was obtained for all patients prior to performing study-related procedures in accordance with federal and institutional guidelines.
: Not applicable.
: LAH, WC, MW, MF, FB, AQ, DC, DM, TB, CH, CR, SPS, KRW, SSu, RNF, and RP are current or former employees of Genentech (a member of the Roche Group), and own stock or stock options in F. Hoffmann-La Roche. SSa received grants and personal fees from Genentech during the conduct of the study, grants and personal fees from Eli Lilly, Biogen Idec, Merck, and Roche, and grants from Functional Neuromodulation, Avid, and Novartis. EMR received grants from Banner Alzheimer’s Institute during the conduct of the study, and is evaluating crenezumab in the Alzheimer’s Prevention Initiative (API) Autosomal Dominant Alzheimer’s Disease Trial. KC declares that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.